Elarekibep

Elarekibep (PRS-060) (AZD1402) is a high affinity, slowly dissociating, long-acting full antagonist of IL-4Ra. Elarekibep can be used for the research of T2 endotype asthma.

Elarekibep (PRS-060) (0-10 µM) inhibits IL-4- or IL-13-induced STAT-6 phosphorylation with IC₅₀ values of 0.12 nM and 0.10 nM, respectively^[1].
PRS-060 (0-10 µM) inhibits hIL-4 or hIL-13 indued proliferation of TF-1 cells with IC₅₀ values of 0.87 nM and 0.92 nM, respectively^[1].
PRS-060 (0-10 µM) inhibits hIL-13 induced human epithelial cell mucus transdifferentiation with an IC₅₀ value of 0.3 nM^[1].

PRS-060 (i.t; 2, 10, 50 µg) inhibits IL-13-induced eotaxin-1 expression in the lung and ovalbumin-induced acute allergic inflammation in the humanized mouse^[1].

References:
[1]. Gabriele Matschiner, et al. Elarekibep (PRS-060/AZD1402): a new class of inhaled Anticalin medicine targeting IL-4Ra for T2 endotype asthma. J Allergy Clin Immunol. 2022 Dec 30;S0091-6749(22)02588-X.